Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4549-4555

  LaPlante, Kerry L ^a,b   Sakoulas, George ^c,d,e  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e SHARP MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTAZIDIME; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MICROBIAL ATTENUATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; ANTI-BACTERIAL AGENTS; AZTREONAM; CEFTAZIDIME; DAPTOMYCIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; VANCOMYCIN;

EID: 70349317374     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00180-09     Document Type: Article

References (29)

1. Asmar, B. I., M. Prainito, and A. S. Dajani. 1988. Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone. Antimicrob. Agents Chemother. 32:1375-1378.
2. Bechard, D. L., S. S. Hawkins, R. Dhruv, and L. T. Friedhoff. 1985. Penetration of aztreonam into human bronchial secretions. Antimicrob. Agents Chemother. 27:263-264.
3. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
4. Boeckh, M., H. Lode, K. Borner, G. Hoffken, J. Wagner, and P. Koeppe. 1988. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob. Agents Chemother. 32:92-95.
5. Bonapace, C. R., J. A. Bosso, L. V. Friedrich, and R. L. White. 2002. Comparison of methods of interpretation of checkerboard synergy testing. Diagn. Microbiol. Infect. Dis. 44:363-366.
6. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; 7th ed. Approved guideline M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th edition. Approved informational supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Dvorchik, B. H., D. Brazier, M. F. DeBruin, and R. D. Arbeit. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323.
9. Eliopoulos, G. M. 1989. Synergism and antagonism. Infect. Dis. Clin. N. Am. 3:399-406.
10. Gee, T., R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise. 2001. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45:1843-1846.
11. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
12. Jawetz, E., J. B. Gunnison, R. S. Speck, and V. R. Coleman. 1951. Studies on antibiotic synergism and antagonism; the interference of chloramphenicol with the action of penicillin. AMA Arch. Intern. Med. 87:349-359.
13. Lamp, K. C., and M. K. Vickers. 1998. Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance. Antimicrob. Agents Chemother. 42:231-235.
14. LaPlante, K. L., and M. J. Rybak. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672.
15. LaPlante, K. L., S. Woodmansee, and G. Sakoulas. 2008. Evaluation of antagonistic activity between linezolid & aztreonam or ceftazidime against Escherichia coli in an in vitro pharmacodynamic model, abstr. A-038, p. 10. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
16. Lepper, M. H., and H. F. Dowling. 1951. Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. AMA Arch. Intern. Med. 88:489-494.
17. Lin, A. H., R. W. Murray, T. J. Vidmar, and K. R. Marotti. 1997. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. 41:2127-2131.
18. Matzke, G. R., G. G. Zhanel, and D. R. Guay. 1986. Clinical pharmacokinetics of vancomycin. Clin. Pharmacokinet. 11:257-282.
19. McKee, E. E., M. Ferguson, A. T. Bentley, and T. A. Marks. 2006. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50:2042-2049.
20. Pfeltz, R. F., J. L. Schmidt, and B. J. Wilkinson. 2001. A microdilution plating method for population analysis of antibiotic-resistant staphylococci. Microb. Drug Resist. 7:289-295.
21. Schmidt, C. A., M. Carazzo, L. V. Laporta, C. F. Bittencourt, M. R. Santos, and M. Friedrich. 2008. Development and validation of an agar diffusion assay for determination of ceftazidime in pharmaceutical preparations. J. AOAC Int. 91:59-66. (Pubitemid 351315744)
22. Schumacher, A., R. Trittler, J. A. Bohnert, K. Kummerer, J. M. Pages, and W. V. Kern. 2007. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J. Antimicrob. Chemother. 59:1261-1264.
23. Stalker, D. J., G. L. Jungbluth, N. K. Hopkins, and D. H. Batts. 2003. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J. Antimicrob. Chemother. 51:1239-1246.
24. Reference deleted.
25. Vinks, A. A., R. N. van Rossem, R. A. Mathot, H. G. Heijerman, and J. W. Mouton. 2007. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob. Agents Chemother. 51:3049-3055.
26. Wilcox, M. H., K. J. Tack, E. Bouza, D. L. Herr, B. R. Ruf, M. M. Ijzerman, R. V. Croos-Dabrera, M. J. Kunkel, and C. Knirsch. 2009. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin. Infect. Dis. 48:203-212.
27. Wilson, D. N., F. Schluenzen, J. M. Harms, A. L. Starosta, S. R. Connell, and P. Fucini. 2008. The oxazolidinone antibiotics perturb the ribosomal peptidyltransferase center and effect tRNA positioning. Proc. Natl. Acad. Sci. USA 105:13339-13344.
28. Wolter, N., A. M. Smith, D. J. Farrell, W. Schaffner, M. Moore, C. G. Whitney, J. H. Jorgensen, and K. P. Klugman. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49:3554-3557.
29. Zinner, S. H., J. Blaser, B. B. Stone, and M. C. Groner. 1985. Use of an in-vitro kinetic model to study antibiotic combinations. J. Antimicrob. Chemother. 15(Suppl. A):221-226.